Literature DB >> 15223430

Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002.

Antonio L Visbal1, Brent A Williams, Francis C Nichols, Randolph S Marks, James R Jett, Marie-Christine Aubry, Eric S Edell, Jason A Wampfler, Julian R Molina, Ping Yang.   

Abstract

BACKGROUND: Gender has been reported as a predictor for nonsmall cell lung cancer (NSCLC) survival. Most of the reports are limited to selected groups of patients. The magnitude of gender effect on NSCLC survival across disease stage, tumor histology, and therapies needs to be further characterized.
METHODS: A cohort of 4,618 patients diagnosed with NSCLC was prospectively enrolled and actively followed. Vital status of each patient was verified through multiple complementary sources. Cox proportional hazards models were developed to compare postdiagnosis survival between genders adjusting for age at diagnosis, tumor histology and grade, stage, pack-years smoked, and treatment received (resection, radiation, or chemotherapy).
RESULTS: There were 2,724 men (59%) and 1,894 women (41%), with a median age at diagnosis of 68 years in men and 66 in women (p < 0.01). More men smoked and were heavier smokers than women. Adenocarcinoma was the most frequent histology in both genders. No difference was found in stage and treatment between genders. The estimated survival in men was 51% (95% CI: 49%, 53%) and 15% (95% CI: 12%, 17%) at one and five years, respectively, and in women was 60% (95% CI: 58%, 62%) and 19% (95% CI: 16%, 22%). Men were at a significantly increased risk of mortality compared to women following a diagnosis of NSCLC (adjusted relative risk: 1.20, 95% CI: 1.11, 1.30), particularly for patients with stage III/IV disease or adenocarcinoma.
CONCLUSIONS: Male gender is confirmed to be an independent unfavorable prognostic indicator for NSCLC survival.

Entities:  

Mesh:

Year:  2004        PMID: 15223430     DOI: 10.1016/j.athoracsur.2003.11.021

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  83 in total

1.  Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599.

Authors:  Julie R Brahmer; Suzanne E Dahlberg; Robert J Gray; Joan H Schiller; Michael C Perry; Alan Sandler; David H Johnson
Journal:  J Thorac Oncol       Date:  2011-01       Impact factor: 15.609

2.  Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer.

Authors:  Hao Zhang; Kristen Wroblewski; Daniel Appelbaum; Yonglin Pu
Journal:  Int J Comput Assist Radiol Surg       Date:  2012-05-30       Impact factor: 2.924

3.  Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types.

Authors:  Matthew D Wilkerson; Xiaoying Yin; Katherine A Hoadley; Yufeng Liu; Michele C Hayward; Christopher R Cabanski; Kenneth Muldrew; C Ryan Miller; Scott H Randell; Mark A Socinski; Alden M Parsons; William K Funkhouser; Carrie B Lee; Patrick J Roberts; Leigh Thorne; Philip S Bernard; Charles M Perou; D Neil Hayes
Journal:  Clin Cancer Res       Date:  2010-07-19       Impact factor: 12.531

Review 4.  Sex-specific aspects of tumor therapy.

Authors:  Kerstin Borgmann; Ekkehard Dikomey; Cordula Petersen; Petra Feyer; Ulrike Hoeller
Journal:  Radiat Environ Biophys       Date:  2009-02-26       Impact factor: 1.925

5.  Interplay between estrogen and Stat3/NF-κB-driven immunomodulation in lung cancer.

Authors:  Shanshan Deng; Marco Ramos-Castaneda; Walter V Velasco; Michael J Clowers; Berenice A Gutierrez; Oscar Noble; Yiping Dong; Melody Zarghooni; Lucero Alvarado; Mauricio S Caetano; Shuanying Yang; Edwin J Ostrin; Carmen Behrens; Ignacio I Wistuba; Laura P Stabile; Humam Kadara; Stephanie S Watowich; Seyed Javad Moghaddam
Journal:  Carcinogenesis       Date:  2020-11-13       Impact factor: 4.944

6.  Gender-specific differences in care-seeking behaviour among lung cancer patients: a systematic review.

Authors:  Rezwanul Hasan Rana; Fariha Alam; Khorshed Alam; Jeff Gow
Journal:  J Cancer Res Clin Oncol       Date:  2020-04-03       Impact factor: 4.553

Review 7.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.

Authors:  Julian R Molina; Ping Yang; Stephen D Cassivi; Steven E Schild; Alex A Adjei
Journal:  Mayo Clin Proc       Date:  2008-05       Impact factor: 7.616

8.  Age and gender differences in medicare expenditures and service utilization at the end of life for lung cancer decedents.

Authors:  Lisa R Shugarman; Chloe E Bird; Cynthia R Schuster; Joanne Lynn
Journal:  Womens Health Issues       Date:  2008 May-Jun

9.  Sex as an independent prognostic factor in a population-based non-small cell lung cancer cohort.

Authors:  Marshall W Pitz; Grace Musto; Srisala Navaratnam
Journal:  Can Respir J       Date:  2013 Jan-Feb       Impact factor: 2.409

10.  Prognosis of smokers following resection of pathological stage I non-small-cell lung carcinoma.

Authors:  Noriyoshi Sawabata; Shinichiro Miyoshi; Akihide Matsumura; Mitsunori Ohta; Hajime Maeda; Hirofumi Sueki; Masanobu Hayakawa; Meinoshin Okumura; Yoshiki Sawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2007-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.